Completed PHASE3 INTERVENTIONAL 2-arm NCT00004208

Antithymocyte Globulin and Cyclosporine in Treating Patients With Myelodysplastic Syndrome

Antithymocyte Globulin (ATG) and Cyclosporine (CSA) to Treat Patients With Myelodysplastic Syndrome (MDS). A Randomized Trial Comparing ATG + CSA With Best Supportive Care

Sponsor: Swiss Cancer Institute

Conditions Myelodysplastic Syndromes

Interventions ATG + CSA Supportive care

Updated 6 times since 2017 Last updated: Mar 10, 2015 Started: Aug 31, 2000 Primary completion: Oct 31, 2006 Completion: Oct 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00004208, this PHASE3 trial focuses on Myelodysplastic Syndromes and remains completed. Sponsored by Swiss Cancer Institute, it has been updated 6 times since 2000, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Aug 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Aug 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Aug 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Swiss Cancer Institute

Data source: Swiss Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Basel, Switzerland